These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 11480710)

  • 1. Cost-effectiveness studies on cervical cancer.
    Brown AD; Raab SS; Suba EJ; Wright RG;
    Acta Cytol; 2001; 45(4):509-14. PubMed ID: 11480710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. De novo establishment and cost-effectiveness of Papanicolaou cytology screening services in the Socialist Republic of Vietnam.
    Levin CE; Sellors JW
    Cancer; 2002 Apr; 94(8):2312-4; author reply 2314-6. PubMed ID: 12001136
    [No Abstract]   [Full Text] [Related]  

  • 3. Cost-effectiveness of cervical cancer screening: comparison of screening policies.
    van den Akker-van Marle ME; van Ballegooijen M; van Oortmarssen GJ; Boer R; Habbema JD
    J Natl Cancer Inst; 2002 Feb; 94(3):193-204. PubMed ID: 11830609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. De novo establishment and cost-effectiveness of Papanicolaou cytology screening services in the Socialist Republic of Vietnam.
    Suba EJ; Nguyen CH; Nguyen BD; Raab SS;
    Cancer; 2001 Mar; 91(5):928-39. PubMed ID: 11251944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ["Cost-effectiveness" of cervical screening].
    Kostova P
    Akush Ginekol (Sofiia); 2007; 46(6):32-4. PubMed ID: 17974169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cost effectiveness of human papilloma virus testing in cervical cancer screening: a literature review].
    Mejía A; Salas W
    Biomedica; 2008 Mar; 28(1):160-72. PubMed ID: 18645671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Online Cost-Effectiveness ANalysis (OCEAN): a user-friendly interface to conduct cost-effectiveness analyses for cervical cancer.
    Moriña D; Martí JI; Puig P; Diaz M
    BMC Med Inform Decis Mak; 2020 Sep; 20(1):211. PubMed ID: 32887589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Costs and problems in cervix cancer screening are considerably underestimated].
    Bistoletti P
    Lakartidningen; 2000 Aug; 97(32-33):3506-8. PubMed ID: 11037597
    [No Abstract]   [Full Text] [Related]  

  • 9. Evaluation of costs and benefits of advances in cytologic technology. International Academy of Cytology Task Force summary. Diagnostic Cytology Towards the 21st Century: An International Expert Conference and Tutorial.
    Melamed MR; Hutchinson ML; Kaufman EA; Schechter CB; Garner D; Kobler TP; Krieger PA; Reith A; Schenck U
    Acta Cytol; 1998; 42(1):69-75. PubMed ID: 9479325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Costs of population cervical cancer screening program in Poland between 2007-2009].
    Spaczyński M; Karowicz-Bilinska A; Kedzia W; Molińska-Glura M; Seroczyński P; Januszek-Michalecka L; Rokita W; Nowak-Markwitz E
    Ginekol Pol; 2010 Oct; 81(10):750-6. PubMed ID: 21117303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does the increased sensitivity of the new Papanicolaou (Pap) tests improve the cost-effectiveness of screening for cervical cancer?
    Reust CE
    J Fam Pract; 2001 Feb; 50(2):175. PubMed ID: 11219567
    [No Abstract]   [Full Text] [Related]  

  • 12. Cost of screening for cancerous and precancerous lesions of the cervix.
    Méréa E; Le Galès C; Cochand-Priollet B; Cartier I; de Crémoux P; Vacher-Lavenu MC; Vielh P; Coste J
    Diagn Cytopathol; 2002 Oct; 27(4):251-7. PubMed ID: 12357505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of organized versus opportunistic cervical cytology screening in Hong Kong.
    Kim JJ; Leung GM; Woo PP; Goldie SJ
    J Public Health (Oxf); 2004 Jun; 26(2):130-7. PubMed ID: 15284314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cost effectiveness analysis of screening strategies for cervical cancer in Tunisia].
    Lazaar HB; Aounallah-Skhiri H; Oueslati F; Frikha H; Achour N; Hsairi M
    East Mediterr Health J; 2010 Jun; 16(6):602-8. PubMed ID: 20799586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The cost of screening for breast and cervical cancer in France].
    Watt S
    Bull Cancer; 2003 Nov; 90(11):997-1004. PubMed ID: 14706904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of cervical-cancer screening in developing countries.
    Suba EJ; Frable WJ; Raab SS
    N Engl J Med; 2006 Apr; 354(14):1535-6; author reply 1535-6. PubMed ID: 16598056
    [No Abstract]   [Full Text] [Related]  

  • 17. [Cervical cancer screening and associated treatment costs in France].
    Bergeron C; Breugelmans JG; Bouée S; Lorans C; Bénard S; Rémy V
    Gynecol Obstet Fertil; 2006 Nov; 34(11):1036-42. PubMed ID: 17070085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis for Pap smear screening and human papillomavirus DNA testing and vaccination.
    Chen MK; Hung HF; Duffy S; Yen AM; Chen HH
    J Eval Clin Pract; 2011 Dec; 17(6):1050-8. PubMed ID: 21679279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cancer of the cervix uteri: analysis of the cost-benefit and efficacy of opportunistic screening versus organized screening].
    Castronovo V; Foidart JM; Boniver J
    Rev Med Liege; 1998 May; 53(5):305-7. PubMed ID: 9689888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cost-effectiveness of a cervical cancer screening programme in the Algarve region, Portugal].
    Novoa Vázquez RM
    Rev Esp Salud Publica; 2004; 78(3):341-53. PubMed ID: 15293955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.